May 7, 2020 -- Certara and DMTC have entered into a research collaboration to evaluate the preventative use of chloroquine in healthcare workers at risk of infection from SARS-CoV-2, the coronavirus strain responsible for COVID-19.
The randomized controlled trial will be led by DMTC, formerly the Defence Materials Technology Centre. The trial will develop mathematical models to understand the viral time course and factors affecting drug exposure and prophylactic response in healthy adult healthcare workers at risk of SARS-CoV-2 infection.
In the study, participants will receive a loading dose followed by weekly doses of chloroquine or placebo to be assessed over a 14-week period.
Certara will provide clinical pharmacology expertise by analyzing the data and conducting exposure-response research to build the model.
Copyright © 2020 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
